Combination of two targeted drugs shows “clinically meaningful” activity in some maligna …

combination of two targeted drugs shows clinically meaningful activity in some malignant brain tumors

Sumary of Combination of two targeted drugs shows “clinically meaningful” activity in some malignant brain tumors:

  • A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
  • The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by 50% or more in one-third of 45 patients with hard-to-treat high-grade gliomas, including glioblastomas, the most aggressive brain tumor.
  • This mutation is found in only two to three percent of patients with high-grade gliomas but is found in up to 60% of certain types of low-grade gliomas.
  • “This is the first time that any targeted drug has been shown to work in glioblastoma in a clinical trial,” said Patrick Wen, MD, first author of the report in The Lancet Oncology and director of the Center for Neuro-Oncology at Dana-Farber.
  • The two drugs paired in the study were dabrafenib and trametinib.
  • Both drugs target proteins in the MAPK pathway, a signaling chain of proteins that acts as a switch for cell growth and can become stuck in the “on” position, causing uncontrolled growth leading to tumors.
  • The patients were not cured, but those who responded to the drugs experienced remarkably durable benefits – by one assessment, the median duration of response was 13.6 months, and by another assessment, it was 36.9 months.
  • The findings are from an ongoing phase 2 study called ROAR (Rare Oncology Agnostic Research) that has been enrolling patients since 2014 in 27 community and academic cancer centers in 13 countries.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.